A Phase 2b Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety
and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to
severely active Ulcerative Colitis (UC).